• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 3. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 4. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

N-[(1-methyl-1H-pyrazol-4-yl)methyl]cyclopropanamine: An Emerging Compound in Medicinal Chemistry

N-[(1-methyl-1H-pyrazol-4-yl)methyl]cyclopropanamine (CAS No. 1100954-16-2) is a promising compound in the field of medicinal chemistry, particularly in the development of novel therapeutic agents. This compound, also known as MPMCPA, has garnered significant attention due to its unique structural features and potential biological activities. In this article, we will delve into the chemical properties, synthesis methods, and recent research findings related to N-[(1-methyl-1H-pyrazol-4-yl)methyl]cyclopropanamine.

The chemical structure of N-[(1-methyl-1H-pyrazol-4-yl)methyl]cyclopropanamine consists of a cyclopropane ring attached to an N-substituted pyrazole moiety. The cyclopropane ring is a three-membered cyclic alkane with a high degree of ring strain, which imparts unique reactivity and conformational properties to the molecule. The pyrazole ring, on the other hand, is a five-membered heterocyclic aromatic compound with two nitrogen atoms. The combination of these structural elements results in a compound with a diverse range of potential biological activities.

Recent studies have highlighted the potential of N-[(1-methyl-1H-pyrazol-4-yl)methyl]cyclopropanamine in various therapeutic areas. One notable application is its use as a modulator of G protein-coupled receptors (GPCRs). GPCRs are a large family of membrane receptors that play crucial roles in cellular signaling pathways and are targets for many drugs. Research has shown that MPMCPA can selectively modulate specific GPCRs, making it a valuable tool for understanding receptor function and developing new therapeutic agents.

In addition to its role in GPCR modulation, N-[(1-methyl-1H-pyrazol-4-yl)methyl]cyclopropanamine has been investigated for its potential as an anti-inflammatory agent. Inflammatory diseases, such as arthritis and inflammatory bowel disease (IBD), are characterized by chronic inflammation and tissue damage. Studies have demonstrated that MPMCPA can inhibit the production of pro-inflammatory cytokines and reduce inflammation in animal models. These findings suggest that N-[(1-methyl-1H-pyrazol-4-yl)methyl]cyclopropanamine may have therapeutic potential in treating inflammatory conditions.

The synthesis of N-[(1-methyl-1H-pyrazol-4-yl)methyl]cyclopropanamine has been optimized using various synthetic routes. One common method involves the reaction of 1-methylpyrazole with an appropriate cyclopropane derivative under mild conditions. This approach allows for the efficient and scalable production of the compound, which is essential for its further development and clinical testing.

Clinical trials are currently underway to evaluate the safety and efficacy of N-[(1-methyl-1H-pyrazol-4-yl)methyl]cyclopropanamine in human subjects. Preliminary results from phase I trials have shown that the compound is well-tolerated at various doses and exhibits favorable pharmacokinetic properties. These findings provide a strong foundation for advancing the compound into later-stage clinical trials.

In conclusion, N-[(1-methyl-1H-pyrazol-4-yl)methyl]cyclopropanamine (CAS No. 1100954-16-2) is a promising compound with diverse biological activities and therapeutic potential. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in medicinal chemistry. As ongoing studies continue to uncover new insights into its mechanisms of action and therapeutic applications, MPMCPA is poised to play a significant role in advancing our understanding of disease mechanisms and developing novel treatments.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)